<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367599</url>
  </required_header>
  <id_info>
    <org_study_id>CCTG 595 Vitamin D Sub-Study</org_study_id>
    <nct_id>NCT02367599</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM</brief_title>
  <acronym>CCTG595VitD</acronym>
  <official_title>Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Long Beach Department of Health and Human Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>California HIV/AIDS Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CCTG 595 is an open-label clinical trial of the effect of a text messaging intervention vs.
      standard of care on adherence to Truvada as PrEP in MSM at increased risk for HIV infection
      (ClinicalTrials.gov Identifier: NCT01761643). Eligible subjects for this matched case control
      substudy will receive vitamin D 4000 IU/day for 24 weeks, from week 24 through week 48. In
      CCTG 595, plasma from participants are being collected and stored at entry and every 12
      weeks. These plasma samples will be used to measure P1NP, CTX, PTH, and vitamin D levels in
      both cases and controls at entry, week 24, and week 48.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 50 HIV-uninfected men who have sex with men (MSM) and male to female (M to F)
      transgender individuals already enrolled in CCTG 595 will be offered participation in the
      sub-study at Week 24 of the main study. All subjects enrolled into the sub-study will be
      provided Vitamin D 4000 IU/day supplements in addition to their PrEP at Weeks 24 and 36;
      clinic visits will proceed normally per main study protocol. Upon completion of the sub-study
      subjects will continue on the main study.

      The primary endpoint, bone turnover markers, will be measured from Week 24 to Week 48 via
      plasma samples collected through the main study. Concurrent controls who are not enrolled in
      the vitamin D substudy who are reporting supplementation with &lt; 400 IU of vitamin D/day will
      be matched 1:1 by randomization arm in the CCTG 595 main study (text messaging arm vs.
      standard of care), age (± 5 years), race/ethnicity, season of study entry, and BMI (± 3
      kg/m2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2014</start_date>
  <completion_date type="Actual">July 11, 2018</completion_date>
  <primary_completion_date type="Actual">June 13, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Procollagen Type 1 N-terminal Propeptide (a Marker of Bone Formation) [P1NP] Levels</measure>
    <time_frame>Weeks 24-48</time_frame>
    <description>To compare the change in P1NP levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CTX-1 Levels</measure>
    <time_frame>Weeks 24-48</time_frame>
    <description>To compare the change in CTX-1 levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTH Levels</measure>
    <time_frame>Weeks 24-48</time_frame>
    <description>To compare the change in PTH levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 25-OH Vitamin D3 Levels</measure>
    <time_frame>Weeks 24-48</time_frame>
    <description>To compare the change in 25-OH vitamin D3 levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Patient Adherence</condition>
  <arm_group>
    <arm_group_label>Vitamin D Supplement + PrEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PrEP Only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D Supplement</intervention_name>
    <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.</description>
    <arm_group_label>Vitamin D Supplement + PrEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must meet CCTG 595 inclusion criteria.

        Exclusion Criteria:

          -  All subjects must meet CCTG 595 exclusion criteria.

          -  Current or prior use of bisphosphonate therapy.

          -  Current use of Vitamin D supplements greater than 400 IU/day.

          -  Current use of androgenic hormones or growth hormones.

          -  History of nephrolithiasis (kidney stones).

          -  History of fragility fracture.

          -  No use of tenofovir prior to entry into CCTG 595
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Dube, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CCTG, USC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheldon Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego AntiViral Research Center (AVRC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>May 13, 2020</results_first_submitted>
  <results_first_submitted_qc>June 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2020</results_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sheldon Morris</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>PrEP</keyword>
  <keyword>Pre exposure Prophylaxis</keyword>
  <keyword>Truvada</keyword>
  <keyword>CCTG</keyword>
  <keyword>595</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Bone mineral density</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02367599/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants in the parent trial (CCTG 595) were offered the opportunity to enroll in this sub-study providing Vitamin D supplementation to HIV pre-exposure prophylaxis (PrEP).</recruitment_details>
      <pre_assignment_details>48 enrolled, 48 matched from parent study. Total 96 evaluated participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D Supplement + PrEP</title>
          <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 weeks in addition to their PrEP provided through the parent trial.</description>
        </group>
        <group group_id="P2">
          <title>PrEP Only Matched Group</title>
          <description>A cohort of parent trial participants will be selected to match subjects enrolled in the sub-study to serve as comparative controls.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D Supplement + PrEP</title>
          <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.</description>
        </group>
        <group group_id="B2">
          <title>PrEP Only Matched Group</title>
          <description>A cohort of main-study participants will be selected to match subjects enrolled in the sub-study to serve as controls for comparison.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" lower_limit="28" upper_limit="37.5"/>
                    <measurement group_id="B2" value="33.0" lower_limit="29" upper_limit="38.5"/>
                    <measurement group_id="B3" value="33.2" lower_limit="28.5" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Procollagen Type 1 N-terminal Propeptide (a Marker of Bone Formation) [P1NP] Levels</title>
        <description>To compare the change in P1NP levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
        <time_frame>Weeks 24-48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Supplement + PrEP</title>
            <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 weeks in addition to their PrEP provided through the parent trial.</description>
          </group>
          <group group_id="O2">
            <title>PrEP Only Matched Group</title>
            <description>A cohort of parent trial participants will be selected to match subjects enrolled in the sub-study to serve as comparative controls.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Procollagen Type 1 N-terminal Propeptide (a Marker of Bone Formation) [P1NP] Levels</title>
          <description>To compare the change in P1NP levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.6" spread="49.9"/>
                    <measurement group_id="O2" value="-2.5" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CTX-1 Levels</title>
        <description>To compare the change in CTX-1 levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
        <time_frame>Weeks 24-48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Supplement + PrEP</title>
            <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 weeks in addition to their PrEP provided through the parent trial.</description>
          </group>
          <group group_id="O2">
            <title>PrEP Only Matched Group</title>
            <description>A cohort of parent trial participants will be selected to match subjects enrolled in the sub-study to serve as comparative controls.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CTX-1 Levels</title>
          <description>To compare the change in CTX-1 levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.12"/>
                    <measurement group_id="O2" value="0.29" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PTH Levels</title>
        <description>To compare the change in PTH levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
        <time_frame>Weeks 24-48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Supplement + PrEP</title>
            <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 weeks in addition to their PrEP provided through the parent trial.</description>
          </group>
          <group group_id="O2">
            <title>PrEP Only Matched Group</title>
            <description>A cohort of parent trial participants will be selected to match subjects enrolled in the sub-study to serve as comparative controls.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PTH Levels</title>
          <description>To compare the change in PTH levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="128.9"/>
                    <measurement group_id="O2" value="108.4" spread="210.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 25-OH Vitamin D3 Levels</title>
        <description>To compare the change in 25-OH vitamin D3 levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
        <time_frame>Weeks 24-48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Supplement + PrEP</title>
            <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 weeks in addition to their PrEP provided through the parent trial.</description>
          </group>
          <group group_id="O2">
            <title>PrEP Only Matched Group</title>
            <description>A cohort of parent trial participants will be selected to match subjects enrolled in the sub-study to serve as comparative controls.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 25-OH Vitamin D3 Levels</title>
          <description>To compare the change in 25-OH vitamin D3 levels from Week 24 through Week 48 among subjects (cases) who receive vitamin D 4000 IU/day to the change in levels seen in matched unsupplemented controls</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="16.2"/>
                    <measurement group_id="O2" value="-0.9" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 24-48</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D Supplement + PrEP</title>
          <description>Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.</description>
        </group>
        <group group_id="E2">
          <title>PrEP Only Matched Group</title>
          <description>A cohort of main-study participants will be selected to match subjects enrolled in the sub-study to serve as controls for comparison.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sheldon Morris</name_or_title>
      <organization>UCSD</organization>
      <phone>6195438080</phone>
      <email>shmorris@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

